BCL2L1 has a functional role in colorectal cancer and its protein expression is associated with chromosome 20q gain

Colorectal cancer (CRC) is the second leading cause of cancer death in the western world. The majority of CRCs, which develop from adenoma precursor lesions, show gain of chromosome arm 20q, where BCL2L1 is located. BCL2L1 is an important apoptosis regulating gene that codes for both an anti‐apoptotic (Bcl‐xL) and a pro‐apoptotic (Bcl‐xS) splice variant. The aim of the present study was to investigate whether BCL2L1 contributes to 20q gain‐driven colorectal adenoma‐to‐carcinoma progression. To this end, the functional role of BCL2L1 in cancer‐related processes was investigated, and differences in BCL2L1 DNA, mRNA, and protein levels were compared between colorectal adenomas and CRCs, as well as between tumours with and without 20q gain. Down‐modulation of BCL2L1 inhibited cell viability and anchorage‐independent growth of CRC cells, while invasion was not affected. BCL2L1 DNA copy number and protein expression were increased in CRCs compared to adenomas (p = 0.00005 and p = 0.03, respectively), while mRNA expression was not. Differences in BCL2L1 protein expression were even more pronounced between tumours with and without 20q gain (p = 0.0001). In conclusion, BCL2L1 is functionally involved in several cancer‐related processes and its protein expression is associated with 20q gain. This supports a role for 20q gain‐dependent expression of BCL2L1 in colorectal adenoma‐to‐carcinoma progression. However, the absence of a direct correlation between BCL2L1 mRNA and protein expression implies that BCL2L1 protein expression is regulated at the post‐transcriptional level by a distinct factor on the 20q amplicon (eg ZNF217, AURKA or miRNAs). Therefore, even though BCL2L1 affects CRC biology in a 20q gain‐dependent manner, it is not likely to be a driver of chromosome 20q gain associated adenoma‐to‐carcinoma progression. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[2]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[3]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[4]  C. Thompson,et al.  bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. , 1994, Development.

[5]  Wessel N. van Wieringen,et al.  CGHcall: Calling aberrations for array CGH tumor profiles. , 2008 .

[6]  E. Schröck,et al.  Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression , 2008, Gut.

[7]  J. Eberle,et al.  Apoptosis induction by Bcl-2 proteins independent of the BH3 domain. , 2008, Biochemical pharmacology.

[8]  H. Grabsch,et al.  High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers , 2009, Virchows Archiv.

[9]  R. L. Hayward,et al.  Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. , 2004, Molecular cancer therapeutics.

[10]  Xiaoqi Liu,et al.  Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Jian Kuang,et al.  Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation , 1998, Nature Genetics.

[12]  Sherif Abou Elela,et al.  Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes , 2008, Molecular Cancer Therapeutics.

[13]  M. Marone,et al.  Bcl-2, Bax, Bcl-xL and Bcl-xS Expression in Neoplastic and Normal Endometrium , 2000, Oncology.

[14]  J. Schouten,et al.  DNA Copy Number Changes at 8q11–24 in Metastasized Colorectal Cancer , 2005, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[15]  A Dabancens,et al.  Quinacrine and copper, compounds with anticonceptive and antineoplastic activity. , 1994, Contraception.

[16]  Ji Luo,et al.  Cancer Proliferation Gene Discovery Through Functional Genomics , 2008, Science.

[17]  T. Lesuffleur,et al.  Resistance of colon cancer cells to long‐term 5‐fluorouracil exposure is correlated to the relative level of Bcl‐2 and Bcl‐XL in addition to Bax and p53 status , 2002, International journal of cancer.

[18]  T. Mitchison,et al.  Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL , 2001, Nature Cell Biology.

[19]  E. Pérez-Payá,et al.  Deciphering the antitumoral activity of quinacrine: Binding to and inhibition of Bcl-xL. , 2009, Bioorganic & medicinal chemistry letters.

[20]  Pamela A. Silver,et al.  An Alternative Splicing Network Links Cell-Cycle Control to Apoptosis , 2010, Cell.

[21]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[22]  Jordy Coffa,et al.  MLPAnalyzer: Data Analysis Tool for Reliable Automated Normalization of MLPA Fragment Data , 2008, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[23]  G. Meijer,et al.  Gain of Chromosome 20q Is an Indicator of Poor Prognosis in Colorectal Cancer , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[24]  M. Marone,et al.  Bcl-2, bax, bcl-x(L) and bcl-x(S) expression in neoplastic and normal cervical tissue. , 2000, Cancer letters.

[25]  Jiuyong Xie,et al.  Regulation of alternative splicing of Bcl-x by IL-6, GM-CSF and TPA , 2004, Cell Research.

[26]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[27]  S. Sen,et al.  Aneuploidy and cancer , 2000, Current opinion in oncology.

[28]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[29]  Gain of chromosome 20 q is an indicator of poor prognosis in colorectal cancer , .

[30]  Yu Fan,et al.  Significance of Bcl-xL in human colon carcinoma. , 2008, World journal of gastroenterology.

[31]  J. Schouten,et al.  Chromosomal instability in flat adenomas and carcinomas of the colon , 2005, The Journal of pathology.

[32]  H. Friess,et al.  Apoptosis Inhibiting Factor Bcl-xL Might Be the Crucial Member of the Bcl-2 Gene Family in Colorectal Cancer , 1998, Digestive Diseases and Sciences.

[33]  Doron Betel,et al.  The microRNA.org resource: targets and expression , 2007, Nucleic Acids Res..

[34]  Lin Lianjie,et al.  The influence of survivin shRNA on the cell cycle and the invasion of SW480 cells of colorectal carcinoma , 2008, Journal of experimental & clinical cancer research : CR.

[35]  I. D'Agnano,et al.  c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. , 2001, The American journal of pathology.

[36]  L. Shkreta,et al.  Protein Kinase C-Dependent Control of Bcl-x Alternative Splicing , 2007, Molecular and Cellular Biology.

[37]  À. Sierra,et al.  Inhibition of apoptosis in human breast cancer cells: Role in tumor progression to the metastatic state , 2002, International journal of cancer.

[38]  John Calvin Reed,et al.  Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. , 1996, Cancer research.

[39]  T. Myers,et al.  An informatics approach identifying markers of chemosensitivity in human cancer cell lines. , 2000, Cancer research.

[40]  Yi-Te Hsu,et al.  Movement of Bax from the Cytosol to Mitochondria during Apoptosis , 1997, The Journal of cell biology.

[41]  H Shinya,et al.  Morphology, anatomic distribution and cancer potential of colonic polyps. , 1979, Annals of surgery.

[42]  S. Curley,et al.  Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. , 1993, The Journal of clinical investigation.

[43]  Junying Yuan,et al.  Caspases in apoptosis and beyond , 2008, Oncogene.